Abstract: AIM To investigate the effect of different doses of terofiban combined with ticagrelor on short-term cardiovascular events and platelet aggregation rate in patients with (NSTEMI). METHODS One hundred and twenty-eight NSTEMI patients in our hospital were included in the study. According to different treatment methods, the patients were divided into ticagrelor group (group A, n=39), the conventional dose of tirofiban combined with ticagrelor group (group B, n=46) and small dose of tirofiban combined with Grillo group (group C, n=41). After 4 weeks of treatment, the platelet aggregation rate, fibrinogen (Fib) level and cardiovascular events, and incidence of adverse events were compared between the three groups. RESULTS After 4 weeks of treatment, the occurrence rate of composite endpoint in group A was significantly higher than those in group B and group C (P<0.05). The platelet aggregation rate and blood Fib levels in group B and group C were significantly lower than those in group A (P<0.05). The incidence of adverse reactions in group B was significantly higher than those in group A and group C (P<0.05). CONCLUSION Conventional dose and small dose of tirofiban combined with ticagrelor can reduce short-term cardiovascular events in NSTEMI patients and enhance the inhibition of platelet aggregation. Small dose of tirofiban reduces the incidence of adverse reactions.